Doxorubicin (DOX), with the advantages of exact curative effects and low price, was used as the first-line chemotherapeutic drug to treat breast cancer for a long time. But the serious toxicity to normal tissues such as cardiotoxicity and development of DOX resistance limit the clinical application of DOX. One of the important mechanisms of DOX resistance is considered as the over-expression of ATP-binding cassette (ABC)
Doxorubicin (DOX), with the advantages of exact curative effects and low price, was used as the first-line chemotherapeutic drug to treat breast cancer for a long time. But the serious toxicity to normal tissues such as cardiotoxicity and development of DOX resistance limit the clinical application of DOX. One of the important mechanisms of DOX resistance is considered as the over-expression of ATP-binding cassette (ABC) 1 . ATP-binding cassette is a protein super-family which can actively pump a broad variety of endogenous molecules and xenobiotics out of cells from low concentration site to high concentration site 2 . P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP-1) and breast cancer resistance protein (BCRP) are the primary ABC protein, which is related to DOX resistance 1, 3, 4 . In recent years, numerous strategies were proposed to reverse DOX resistance. An important method to overcome DOX resistance is to use two or more chemotherapeutic drugs with different anti-tumor mechanisms 5 . However, the pharmacokinetic properties of different drugs are vastly different. Therefore, just using two or more free chemotherapeutic drugs without controlling their delivery and release characteristic can not effectively overcome DOX resistance or enhance the anticancer effects of the drugs 6, 7 . The nanoparticles that co-delivered anticancer drug and ABC transporter inhibitor showed great improvement in the efficacy of chemotherapeutic drug [8] [9] [10] . Many researchers have found that resveratrol (RES) can inhibit P-gp activity and subsequently increase the intracellular accumulation of the chemotherapeutic drug. Eventually, RES improve the sensitivity of tumor cells to the chemotherapeutic drug [11] [12] [13] [14] . Besides, Shukla Y. et al. found that RES increased the chemosensitivity of DOX to breast cancer cells through inducing apoptosis in tumor cells and inhibiting proliferation and invasion of tumor cells 15 . Furthermore, RES can reduce cardiac toxicity and fibrosis that induced by DOX 16, 17 . However, the metabolism of RES is extremely rapid and extensive, and its plasma half-life is only about 9 min in human 18 . Moreover, the oral bioavailability of RES is nearly zero due to its poor water solubility and significant first-pass effect [18] [19] [20] . On the other side, the half life of free DOX is about 30~40 h in human 21, 22 . Therefore, just using the Synthesis of CHO-hyd-PEG-AA. CHO-hyd-PEG-AA was synthesized according to Supplementary Figure 1 .
The cholesterol (5.0 g, 13 mmol) was dissolved in dichloromethane (20 mL) , and succinic anhydride (1.9 g, 19 mmol), DMAP (771.1 mg, 6.4 mmol) and TEA (910.7 mg, 9 mmol) were successively added into the dichloromethane solution. The mixture was stirred at room temperature for 24 h. Then the cholesterol-hemisuccinate (CHO-suc) was separated and purified by silica gel column (petroleum ether/ethyl acetate, v/v = 1/2). Then, the CHO-suc (486.4 mg, 1.0 mmol), EDC (191.0 mg, 1.0 mmol) and NHS (115.1 mg, 1.0 mmol) were dissolved in dichloromethane (6 mL), and the reaction mixture was stirred for 6 h at room temperature. Then Boc-NH-NH 2 (132.2 mg, 1 mmol) and TEA (0.1 mL) were added to the reaction mixture, and the reaction mixture was stirred for 12 h at room temperature. The dichloromethane was evaporated, and cholesterol-succinic-NH-NH-Boc was purified by silica gel column (petroleum ether/ethyl acetate, v/v = 2/1). Finally, cholesterol-succinic-NH-NH-Boc was dissolved in dichloromethane (2 mL), and the catalytic amount of TFA (0.5 mL) was added. The mixture was stirred for 2 h at room temperature. The reaction mixture was washed with water (20 mL) for three times. The organic phase was collected and evaporated. The residue was purified by silica gel column (petroleum ether/ethyl acetate, v/v = 2/1) to get cholesterol-succinic-NH-NH 2 (CHO-NH-NH 2 ).
AA-PEG-4-acetylbenzoic acid was synthesized by using p-anisoyl chloride, PEG and 4-acetylbenzoic acid 26 . The AA-PEG-4-acetylbenzoic acid (150.3 mg, 0.03 mmol) and CHO-NH-NH 2 (30.2 mg, 0.06 mmol) were dissolved in 5 mL dichloromethane and the catalytic amount of TFA (0.2 mL) was added, and the mixture was stirred for 8 h at room temperature. After that, the reaction solvent was evaporated, and the residue was dissolved in water (20 mL). The solution was removed into dialysis tube, and it was dialyzed in water for 48 h. The solution in dialysis tube was freeze-dried to get CHO-hyd-PEG-AA.
Preparation and characterization of DOX/RES-loaded PLGA nanoparticles (NPS). DOX/
RES-loaded NPS was prepared by using emulsion-solvent evaporation method. Briefly, 10 mg PLGA and 5 mg CHO-hyd-PEG-AA were dissolved in dichloromethane (3 mL), 8 mg RES was dissolved in ethanol (0.5 mL), and 3 mg DOX·HCl was dissolved in distilled water (6 mL). The above solution was mixed and emulsified by using ultrasound for 3 min at 0 °C. After that, 0.3% PVA (10 mL) was added into the mixture solution and further emulsified by using ultrasound for 3 min at 0 °C. Finally, the mixture solution was stirred at room temperature for 4 h to remove dichloromethane. After centrifugation, the precipitation was re-suspended in water, and then frozen-dried to obtain DOX/RES-loaded NPS powder. The zeta potential and size distribution of DOX/ RES-loaded NPS were detected at room temperature by zeta-potential & particle size analyzer (Beckman Coulter, Miami, USA). The morphology of DOX/RES-loaded NPS was observed by transmission electron microscopy (TEM, JEOL, Japan). The drug loading (DL) and drug release characteristic from DOX/RES-loaded NPS in vitro were determined by using 970 CRT fluorescence spectrophotometer (Shanghai Precision & Scientific Instrument Co. Ltd, Shanghai, China).
Cytotoxicity of DOX/RES-loaded NPS.
The store solution of RES was prepared by using dimethylsulfoxide (DMSO). The final RES solution used to treat cell contained less than 0.3% DMSO. DOX·HCl and DOX/ RES-loaded NPS was directly dissolved with cell culture medium.
MDA-MB-231/ADR cells and MCF-7/ADR cells were seeded in 96-well plates at a density of 5 × 10 4 cells/mL and cultured for 24 h. The culture medium was replaced by fresh RPMI 1640 (200 μ L) or fresh RPMI 1640 containing blank NPS, DOX/RES-loaded NPS, free DOX, free RES and MIX (a mixture of free DOX and free RES), and the cells were cultured for 48 h. Then, 20 μ L MTT solution (5 mg/mL) was added into each well and incubated the cells for another 4 h. Finally, cell culture medium was replaced by 200 μ L DMSO, and the absorbance (OD) of DMSO solution was detected by using the microplate reader (Bio-Rad Laboratories, Inc. Richmond, California, USA) at 490 nm. Cell viability was calculated by the following formula:
treated cells control cells
Caspase 3 activity induced by DOX/RES-loaded NPS.
To evaluate the effect of DOX/RES-loaded NPS on caspase 3 activity in MDA-MB-231/ADR cells and MCF-7/ADR cells, cells were seeded in 6-well plates at a density of 5 × 10 5 cells/mL and incubated for 24 h. Then the cells were exposed to DOX/RES-loaded NPS, free DOX, free RES and MIX (the equivalent concentration of RES was 60 μ g/mL and 90 μ g/mL, the equivalent concentration of DOX was 20 μ g/mL and 30 μ g/mL, respectively) for 24 h. Caspase 3 activity assay kit (Beyotime Biotechnology, China) was used to detect caspase 3 activity in MDA-MB-231/ADR cells and MCF-7/ADR cells. Cellular uptake of DOX/RES-loaded NPS. RES shows green fluorescence whereas DOX shows red fluorescence. Confocal laser scanning microscopy was used to evaluate cellular uptake of DOX/RES-loaded NPS. MDA-MB-231/ADR cells and MCF-7/ADR cells were respectively seeded in 24-well plates with a cover glass in each well (5 × 10 4 cells/mL) and incubated for 24 h. Then the cells were incubated with DOX/RES-loaded NPS, free DOX, free RES and MIX (the equivalent concentration of RES and DOX was 30 μ g/mL and 10 μ g/mL, respectively) for 4 h. The culture medium was then removed, and the cells were slightly washed with PBS for 3 times. The cells were exposed to 500 μ L DAPI (100 μ g/mL, Invitrogen Technologies Company, Carlsbad, USA) for 15 min. After DAPI medium had been removed, the cells were slightly washed 3 times with PBS. After that, the cells were fixed for 15 min at room temperature by using 4% paraformaldehyde. Finally, the glycerol was dropped on slides to seal cell samples. The Olympus FV10-ASW (Tokyo, Japan) was used to detect the localization of RES green fluorescence and DOX red fluorescence in the cell, and Image Jv1.47 software packages were used to quantitatively analyze the relative fluorescence intensity in the cell.
Cell cycle analysis. Flow cytometry was used to evaluate the effect of DOX/RES-loaded NPS on the cell cycle. Briefly, MCF-7/ADR cells and MDA-MB-231/ADR cells were seeded at a density of 5 × 10 5 cells/mL in 6-well plates and incubated for 12 h. Then the cells were culture with the serum-free RPMI 1640 (200 μ L) for 12 h to synchronize the cells. After that, the culture medium was replaced by fresh RPMI 1640 (200 μ L) or fresh RPMI 1640 containing DOX/RES-loaded NPS, free DOX, free RES and MIX (the equivalent concentration of RES and DOX was 60 μ g/mL and 20 μ g/mL, respectively), and the cells were incubated for 24 h. Then the cells were harvested and suspended in 75% ethanol at 4 °C for 12 h. The cells were collected by centrifugation. Finally, the cells were incubated with mixture of Triton X-100 (0.1%,v/v), RNAseA (1 μ g/mL) and propidium iodide (0.2 mg/mL) at 37 °C for 1 h. Cell cycle was detected by flow cytometry (BD FACSAria, USA).
In addition, after being treated with DOX/RES-loaded NPS for 24 h, cells were harvested and lyzed with RIPA lysis buffer for 15 min. The supernatant was collected after the cells lysis was centrifugated (16000 × g, 4 °C) for 15 min, and the protein concentration was quantified by Bradford reagent. The cell cycle-related proteins were analyzed by western blot. (about 170 mm 3 ), the mice were randomly divided into 6 groups (5 mice/each group). The tumor-bearing mice were intravenously injected with DOX/RES-loaded NPS (equivalent DOX dose was 5 and 10 mg/kg, respectively), DOX (5 and 10 mg/kg), RES (30 mg/kg) and normal saline every 5 th day. The mice were observed and weighted every day. Tumor growth was monitored by measuring the perpendicular diameter of the tumor using a caliper. The tumor volume was calculated according to the following formula: tumor volume (mm 3 ) = 0.5 × length × width 2 . The level of drug resistance-related protein and apoptosis-related protein in tumor tissue were measured by western blot method at the end of the experiment.
In vivo drug distribution. The tumor-bearing mice were intravenously injected with DOX/RES-loaded NPS (equivalent DOX and RES dose was 10 mg/kg and 30 mg/kg, respectively), DOX (10 mg/kg) and RES (30 mg/kg) by tail vein. After drug was administered for 12, 24 and 48 h, the mice were sacrificed. Tumor tissues and organs were excised and rinsed in PBS (pH 7.4), and Caliper IVIS Lumina II in-vivo image system (Caliper Life Science, USA) was used to evaluate the time-dependent drug distribution in tumor tissues and various organs. Living Image 4.2 software was used to quantitatively analyze the fluorescence intensity in tumor tissues and organs. At the same time, the tumor tissues and organs were cut to 5 μ m thickness sections, and sections were stained with DAPI (100 μ g/mL). Fluorescence microscopy (DS-5M-ui80i, Nikon Corporation, Japan) was used to observe RES green fluorescence and DOX red fluorescence in the section of tumor tissues and organs. Statistical Analysis. Data were expressed as the mean ± standard deviation. The comparison of each group was assessed by using one-way ANOVA analysis of Origin8 software (SPSS Inc., Chicago, IL, USA). The level of significance was indicated by *p < 0.05, **p < 0.01.
Results
Characterization of CHO-hyd-PEG-AA. The 1 HNMR spectrum and infrared spectrum of CHO-hyd-PEG-AA are presented in Supplementary Figures 2 and Fig. 3 . The AA in CHO-hyd-PEG-AA was confirmed by the signals at peak a, b, c, d, f (δ = 2.38, δ = 8.2, δ = 7.74, δ = 6.19, δ = 1.46). The signal at peak g (δ = 3.6 ppm) confirmed the PEG backbone in the conjugate. The signal at peak h (δ = 5.35 ppm) confirmed the CHO backbone in the conjugate. The characteristic absorbance for PEG was verified in 1113/cm (C-O-C) and about 774/cm (C-H). The absorption at about 1661/cm was attributable to C= N of the hydrazone bond.
Characterization of NPS. The particle size distribution, TEM images, and stability in water of DOX/ RES-loaded NPS are showed in Fig. 1A -C, respectively. The particle size of DOX/RES-loaded NPS was 170 nm with the polydispersity index (PDI) of 0.14. The zeta potential of DOX/RES-loaded NPS was − 15.8 ± 0.8 mV. The TEM image showed that DOX/RES-loaded NPS was generally spherical in shape and kept good dispersity. The drug loading of NPS was (4.6 ± 1.4)% for DOX and (15.5 ± 5.3)% for RES. The release rate of DOX and RES from the DOX/RES-loaded NPS in different pH medium is showed in Fig. 1D ,E. DOX/RES-loaded NPS released out 44% of loaded DOX and 42% of loaded RES in 24 h in pH 7.4 medium. However, in pH 5.0 medium, DOX/ RES-loaded NPS released out 73% of loaded DOX and 81% of loaded RES in 24 h, respectively. This result implied that DOX and RES from NPS exhibited pH-dependent manner. Figure 4A ,B, blank NPS did not exhibit significant cytotoxicity both on MDA-MB-231/ADR cells and MCF-7/ADR cells as dose ranged from 50 to 800 μ g/mL. The cytotoxicity of DOX/RES-loaded NPS on MDA-MB-231/ADR cells and MCF-7/ADR cells are showed in Fig. 2A Cell cycle progression is positively regulated by the cyclins and cyclin-dependent kinases (CDKs) 27 . In order to investigated the mechanism that DOX/RES-loaded NPS arrested the cell cycle in G1 phase, the cell cycle related protein was determined by west blot, and the results are showed in Fig. 4C . DOX/RES-loaded NPS significantly reduced the expression of cyclin A1, cyclin D1, CDK2 and CDK4 in MDA-MB-231/ADR cells, which resulted in a G1 phase arrest. The mixture of DOX and RES showed the same effect as DOX/RES-loaded NPS. In addition, free DOX remarkably reduced the expression of cyclin D1 and CDK2 in MDA-MB-231/ADR cells. RES significantly reduced the expression of cyclin A1 and CDK4 in MDA-MB-231/ADR cells.
Cytotoxicity of DOX/RES-loaded NPS. As showed in Supplementary
The effect of DOX/RES-loaded NPS on the cell cycle and cell cycle-related protein in MCF-7/ADR cells is showed in Supplementary Figure 5 . The results exhibited the same tendency as in MDA-MB-231/ADR cells. Fig. 5A , free DOX (20 μ g/mL) obviously increased the expression of NF-κ B in MDA-MB-231/ADR cells. However, free RES significantly decreased the expression of NF-κ B in MDA-MB-231/ADR cells. Besides, free DOX decreased the expression of Bax and showed no effect on expression of BCL-2 in MDA-MB-231/ADR cells. Free RES (60 μ g/mL) showed no effect on the expression of BCL-2 and Bax in MDA-MB-231/ADR cells. The mixture of DOX and RES obviously increased the expression of Bax and decreased the expression of NF-κ B and BCL-2. Compared with free RES, the mixture of DOX and RES showed the stronger effect on NF-κ B/BCL-2/Bax signal pathway. DOX/RES-loaded NPS (the equivalent concentration of RES and DOX was 60 μ g/mL and 20 μ g/mL, respectively) also significantly inhibited the expression of NF-κ B and BCL-2 and increased the expression of Bax in MDA-MB-231/ADR cells. The effect of DOX/RES-loaded NPS on apoptosis-related protein in MCF-7/ADR cells is showed 
The effect of DOX/RES-loaded NPS on apoptosis-related protein in MDA-MB-231/ADR cells and MCF-7/ADR cells. As showed in

In vivo anti-tumor activity of DOX/RES-loaded NPS. The in vivo antitumor activities of DOX/
RES-loaded NPS are showed in Fig. 7 . The tumor volume increased fast when tumor-bearing mice were treated with normal saline. Meanwhile, after tumor-bearing mice were treated with 5 mg/kg free DOX, the tumor volume did not decrease as compared with normal saline treated tumor-bearing mice. 10 mg/kg free DOX significantly decreased the tumor volume. Besides, DOX/RES-loaded NPS obviously inhibited tumor growth in dose-dependent manner. In addition, as showed in Fig. 7B , the body weight significantly decreased in free DOX-treated tumor-bearing mice, while DOX/RES-loaded NPS did not cause significant body weight loss. Moreover, in 25 days, all tumor-bearing mice died in 10 mg DOX/kg treated group.
Drug resistance-related protein and apoptosis-related proteins expressed in tumor tissue.
After tumor-bearing mice were treated with DOX/RES-loaded NPS (10 mg DOX/kg), the expression of apoptosis-related protein and drug resistance-related protein in tumor tissue were determined by western blot. The results are showed in Fig. 8C ,D. Compared with the tumor tissue from normal saline treated mice, the expression of Bax and caspase-3 were obviously up-regulated, and the expression of p-gp, MRP-1, BCRP, NF-κ B and BCL-2 was remarkably down-regulated in the tumor tissue from DOX/RES-loaded NPS treated tumor-bearing mice. Free DOX (10 mg/kg) significantly dereased the protein expression of BCL-2 and BCRP, while markedly increased the protein expression of Bax, p-gp and NF-κ B as compared with control group.
The distribution of DOX and RES in tumor-bearing mice. The distribution of DOX and RES in tumor-bearing mice is showed in Figs 9 and 10. DOX and RES were mainly distributed in the brain, liver, and kidney, only some amount of DOX and RES was distributed in tumor tissue after free DOX (10 mg/kg) or free RES (30 mg/kg) were respectively administered to tumor-bearing mice by tail vein. However, a large amount of DOX and RES distributed in tumor tissue, while only a little amount of DOX and RES were distributed in normal tissues after DOX/RES-loaded NPS (10 mg DOX/kg, 30 mg RES/kg) were administered. Compared with free DOX, DOX/RES-loaded NPS significantly reduced the distribution of DOX in heart tissue. Besides, a relative high level of DOX and RES in tumor tissue was maintained for a longer time after DOX/RES-loaded NPS was administered.
As showed in Fig. 8A , after free DOX (10 mg/kg) and free RES (30 mg/kg) were respectively administered to tumor-bearing mice by tail vein, only a little amount of DOX and RES were distributed in the section of tumor tissue. However, both DOX and RES were extensively distributed in the section of tumor tissue after DOX/ RES-loaded NPS (10 mg DOX/kg) was administered. H&E staining analysis. After tumor-bearing mice had been treated with DOX/RES-loaded NPS (10 mg DOX/kg), the H&E staining sections of heart, liver, spleen, lung, and kidney from tumor-bearing nude mice are showed in Fig. 11 . No obvious histopathological changes were observed in heart, kidney, liver, spleen, and lung section from DOX/RES-loaded NPS treated tumor-bearing nude mice. Nevertheless, the cardiac section from DOX-treated (10 mg/kg) tumor-bearing nude mice showed marked neutrophils infiltration. Also, as shown in Fig. 8B , obviously histopathological changes were observed in tumor tissue section from DOX/RES-loaded NPS (10 mg DOX/kg) treated tumor-bearing mice.
Discussion
There are four release mechanisms for PLGA nanoparticle to release drug: (1) diffusion via water-filled pores in PLGA nanoparticle, (2) diffusion through PLGA polymer, (3) osmotic pressure in PLGA nanoparticle, and (4) degradation of PLGA 28 . The degradation of PLGA mainly occurs by ester bond broken in the polymer backbone between glycolic acid and lactic acid. In fact, the degradation of PLGA in vitro and in vivo is very slow 29, 30 . Thus, diffusion via water-filled pores is the most common mechanism for PLGA nanoparticle to release drug 28 . DOX/RES-loaded NPS exhibited a biphasic drug release pattern in pH 7.4, pH 6.4 and pH 5.0 medium. The initial burst release was mainly due to the release of DOX and RES encapsulated in outer lipid layer of NPS. The initial burst release followed a sustained release process. The sustained release of DOX and RES from NPS was attributed to diffusion-mediated release from nanoparticles and the gradual degradation and corrosion of PLGA matrix 31 . Furthermore, the faster release of DOX and RES from NPS in pH 5 medium was resulted from the broken of hydrazone linkage between the CHO and PEG. This characteristic led to the burst release of DOX and RES in the lysosome of tumor cells.
The Because the main action target of DOX is nuclear DNA, thus the cellular uptake and intracellular localization of DOX and RES delivered by DOX/RES-loaded NPS were observed by confocal laser scanning microscopy (CLSM). The results indicated that RES increased the cellular accumulation of DOX, and DOX/RES-loaded NPS enhanced the accumulation of DOX and RES in the nucleus. In addition, compared with free RES, the cellular uptake of RES was greater in the mixture of DOX and RES group. This phenonema is interesting, and the exact mechanism is worth to further investigate. Moreover, compared with MCF-7/ADR cells, DOX/RES-loaded NPS delivered more DOX and RES to the nucleus of MDA-MB-231/ADR cells. Aydar E. found that MDA-MB-231 cells expressed much more sigma receptor as compared with MCF-7 cells 24 . Because DOX/RES-loaded NPS was modified with a ligand of Sigma receptor, it was easy for DOX/RES-loaded NPS to bind itself with sigma receptor over-expressed tumor cells and delivered much amount of DOX and RES into MDA-MB-231/ADR cells 32 . Consequently, DOX/RES-loaded NPS showed greater cytotoxicity on MDA-MB-231/ADR cells than on MCF-7/ ADR cells.
When DNA is damaged, the cell cycle is stagnated at G1 phase 33, 34 . The experimental results indicated that DOX/RES-loaded NPS arrested the cell cycle in G1 phase, while free DOX arrested the cell cycle in G2 phase in MDA-MB-231/ADR cells and MCF-7/ADR cells. Cell cycle progression is positively regulated by the cyclins and cyclin-dependent kinases. Cyclin A plays a crucial role in both S phase and G2/M transition in the cell cycle. Cyclin D1 regulates the progression of G1 to S phase. The cyclin-CDK complexes are involved in different periods of the cell cycle. The formation of cyclin A and CDK2 dimer complex initiates S phase. The formation of cyclin D and CDK4 complex promotes cell through G1/S checkpoint to S phase 35 . In order to investigated the mechanism that DOX/RES-loaded NPS arrested the cell cycle in G1 phase, the cell cycle-related protein was determined by western blot. The experimental results indicated that through inhibiting the formation of cyclin A and CDK2 dimers complex as well as cyclin D and CDK4 complex, DOX/RES-loaded NPS induced G1 phase arrest in MDA-MB-231/ADR cells and MCF-7/ADR cells.
It was reported that NF-κ B stimulated the proliferation and inhibited the apoptosis of human breast cancer cells 36 . Activation of NF-κ B led to autoimmune disease and cancer. In mammals, Bcl-2 is called as an anti-apoptosis gene, which can suppress cell apoptosis and protects cell from various cytotoxic attack. BAX is called as a pro-apoptosis gene, which can promote cell apoptosis. The ratio between BCL-2 and Bax determines survival or death after cells are stimulated with an apoptotic signal 37 . BCL-2 is regulated by NF-κ B-dependent transcription 38 . This indicates NF-κ B/BCL-2/Bax signal pathway is involved in regulating cell proliferation, differentiation, and apoptosis 25, 39, 40 . Therefore, the effects of DOX/RES-loaded NPS on the NF-κ B/BCL-2/Bax signal pathway were investigated. The results indicated that DOX/RES-loaded NPS significantly inhibited the expression of NF-κ B and BCL-2, and increased the expression of Bax in MDA-MB-231/ADR cells and MCF-7/ADR cells. This implied that when RES and DOX were co-delivered into tumor cells by DOX/RES-loaded NPS, the expression of NF-κ B was down-regulated. Subsequently, the ratio between BCL-2 and Bax was decreased, and the activity of caspase-3 was increased, which led to the apoptosis of DOX-resistant tumor cells.
Furthermore, the recent work has showed that NF-κ B also involves in drug resistance. Up-regulation of NF-κ B results in drug resistance through increasing the expression of ABCs multidrug transport protein in human cancer cells [41] [42] [43] [44] [45] . The western blot results indicated that DOX/RES-loaded NPS significantly inhibited the expression of NF-κ B and ABC multidrug transport proteins such as MRP-1, P-gp and BCRP in MDA-MB-231/ADR cells and MCF-7/ADR cells. Therefore, the efflux of DOX from DOX-resistant tumor cells was blocked by using DOX/RES-loaded NPS. Consequently, DOX resistance in MDA-MB-231/ADR cells and MCF-7/ADR cells was reversed, and the antitumor activity was enhanced.
The nonselective distribution of DOX in the normal organs results in the serious systemic toxicity, which limits the clinic application of DOX. The in vivo experiments indicated DOX/RES-loaded NPS could simultaneously deliver DOX and RES to tumor tissue and increased the accumulation of DOX and RES in tumor tissue. Meanwhile, the distribution of DOX and RES in normal tissue was obviously reduced. Compared with free DOX, DOX/RES-loaded NPS obviously decreased the distribution of DOX in heart tissue. Consequently, DOX/ RES-loaded NPS decreased cardiotoxicity of DOX. However, free DOX treatment caused obviously histopathological changes in cardiac tissue and showed marked neutrophils infiltration in cardiac section.
In addition, the protein expression of NF-κ B, BCL-2, MRP-1, P-gp, and BCRP were down-regulated, and expression of caspase-3 and Bax were up-regulated in tumor tissue by using DOX/RES-loaded NPS. Those results implied that DOX/RES-loaded NPS increased the accumulation of DOX and RES in DOX-resistant tumor cells by down-regulating of p-gp, MRP-1 and BCRP expression in vivo. At the same time, DOX/RES-loaded NPS induced the tumor cells aptotosis by decreasing BCL-2 expression and increasing Bax and caspase-3 expression in vivo. Eventually, the DOX resistance was overcome, and the antitumor activity was enhanced by using DOX/ RES-loaded NPS.
In a word, DOX/RES-loaded NPS could overcome the DOX resistance and had the potential in the treatment of DOX-resistant breast cancer.
